KR20220119090A - 인자 XI/XIa 항체에 대한 제약 제제 및 투여 요법 - Google Patents

인자 XI/XIa 항체에 대한 제약 제제 및 투여 요법 Download PDF

Info

Publication number
KR20220119090A
KR20220119090A KR1020227024670A KR20227024670A KR20220119090A KR 20220119090 A KR20220119090 A KR 20220119090A KR 1020227024670 A KR1020227024670 A KR 1020227024670A KR 20227024670 A KR20227024670 A KR 20227024670A KR 20220119090 A KR20220119090 A KR 20220119090A
Authority
KR
South Korea
Prior art keywords
antibody
seq
chain variable
variable region
drug delivery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227024670A
Other languages
English (en)
Korean (ko)
Inventor
데브라 에이. 프레드홀름
다니엘 엠. 블룸필드
로이스턴 제이. 글래스풀
조나단 이. 프리만
Original Assignee
안토스 테라퓨틱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 안토스 테라퓨틱스, 인크. filed Critical 안토스 테라퓨틱스, 인크.
Publication of KR20220119090A publication Critical patent/KR20220119090A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
KR1020227024670A 2019-12-20 2020-12-18 인자 XI/XIa 항체에 대한 제약 제제 및 투여 요법 Pending KR20220119090A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962951887P 2019-12-20 2019-12-20
US62/951,887 2019-12-20
PCT/US2020/066151 WO2021127525A1 (en) 2019-12-20 2020-12-18 Pharmaceutical formulations and dosage regimens for factor xi/xia antibodies

Publications (1)

Publication Number Publication Date
KR20220119090A true KR20220119090A (ko) 2022-08-26

Family

ID=76478578

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227024670A Pending KR20220119090A (ko) 2019-12-20 2020-12-18 인자 XI/XIa 항체에 대한 제약 제제 및 투여 요법

Country Status (9)

Country Link
US (1) US20230071973A1 (https=)
EP (1) EP4076511A4 (https=)
JP (2) JP2023507795A (https=)
KR (1) KR20220119090A (https=)
CN (1) CN115003325A (https=)
BR (1) BR112022012064A2 (https=)
CA (1) CA3161118A1 (https=)
IL (1) IL293367A (https=)
WO (1) WO2021127525A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024540435A (ja) * 2021-11-18 2024-10-31 アントス セラピューティクス， インコーポレイテッド 第ＸＩ／ＸＩａ因子抗体の投薬レジメン
TW202333789A (zh) * 2022-01-05 2023-09-01 大陸商上海邁晉生物醫藥科技有限公司 一種包含抗ＦＸＩ／ＦＸＩａ抗體的醫藥組成物及其用途
DE102022116219A1 (de) * 2022-06-29 2024-01-04 St. Jude Medical, Cardiology Division, Inc. Kandidatenscreening für eine Zieltherapie

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8476239B2 (en) * 2005-12-20 2013-07-02 Bristol-Myers Squibb Company Stable protein formulations
US20100129379A1 (en) * 2006-09-25 2010-05-27 John Carpenter Stabilized antibody formulations and uses thereof
CN106038481A (zh) * 2007-06-28 2016-10-26 锡德克斯药物公司 皮质类固醇水溶液的鼻部和眼部给药
LT2953969T (lt) * 2013-02-08 2019-12-10 Novartis Ag Anti-il-17a antikūnai ir jų panaudojimas autoimuninių ir uždegiminių ligų gydymui
UY36751A (es) * 2015-06-26 2017-01-31 Novartis Ag Anticuerpos de factor xi y métodos de uso
MX2018002166A (es) * 2015-08-20 2018-09-12 Abbvie Stemcentrx Llc Conjugados anticuerpo anti-dll3-farmaco y metodos de uso.
IL267519B2 (en) * 2016-12-23 2025-04-01 Novartis Ag Factor XI/XIA for use in the prevention, treatment, management, or reduction of the risk of stroke or thromboembolism in a patient with end-stage renal disease
AU2017383232B2 (en) * 2016-12-23 2024-09-12 Novartis Ag Factor XI antibodies and methods of use
US20190367636A1 (en) * 2017-01-19 2019-12-05 Bayer Pharma Aktiengesellschaft Novel stable formulation for fxia antibodies
JOP20190260A1 (ar) * 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
EP3713965A1 (en) * 2017-11-22 2020-09-30 Novartis AG Reversal binding agents for anti-factor xi/xia antibodies and uses thereof
JP2024540435A (ja) * 2021-11-18 2024-10-31 アントス セラピューティクス， インコーポレイテッド 第ＸＩ／ＸＩａ因子抗体の投薬レジメン

Also Published As

Publication number Publication date
BR112022012064A2 (pt) 2022-08-30
JP2023507795A (ja) 2023-02-27
EP4076511A4 (en) 2024-02-14
WO2021127525A1 (en) 2021-06-24
EP4076511A1 (en) 2022-10-26
IL293367A (en) 2022-07-01
JP2026048712A (ja) 2026-03-17
CN115003325A (zh) 2022-09-02
US20230071973A1 (en) 2023-03-09
CA3161118A1 (en) 2021-06-24

Similar Documents

Publication Publication Date Title
JP7823009B2 (ja) 第ｘｉ因子抗体および使用方法
JP7500662B2 (ja) 抗第ＸＩ／ＸＩａ因子抗体による処置法
JP2022105625A (ja) 高濃度抗ｃ５抗体製剤
JP7003354B2 (ja) 遺伝性血管性浮腫の発作を治療するための血漿カリクレイン阻害薬およびその用途
JP2026048712A (ja) 第ＸＩ／ＸＩａ因子抗体の医薬製剤および投薬レジメン
US20240294669A1 (en) Dosing regimens of factor xi/xia antibodies
KR20250037482A (ko) 항-인자 xi/인자 xia 항체와의 조합 요법
CN118302196A (zh) 因子XI/XIa抗体的给药方案
RU2847356C2 (ru) Антитела к фактору xi и способы их применения
EA045920B1 (ru) Ингибиторы калликреина плазмы и их применение для лечения обострения наследственного ангионевротического отека
BR112017027778B1 (pt) Anticorpo anti-fxi e/ou anti-fxia ativado isolado, usos do mesmo, composição farmacêutica, medicamento, sequência de ácido nucleico, e vetor

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902